CN109963555A - 一种包含美洛昔康的可注射的药物组合物及其制备方法 - Google Patents

一种包含美洛昔康的可注射的药物组合物及其制备方法 Download PDF

Info

Publication number
CN109963555A
CN109963555A CN201880004385.5A CN201880004385A CN109963555A CN 109963555 A CN109963555 A CN 109963555A CN 201880004385 A CN201880004385 A CN 201880004385A CN 109963555 A CN109963555 A CN 109963555A
Authority
CN
China
Prior art keywords
meloxicam
pharmaceutical composition
surface stabilizer
composition according
sedimentation inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004385.5A
Other languages
English (en)
Other versions
CN109963555B (zh
Inventor
孙琼
史海贤
刘凯
刘廷
侍从建
陈新新
柴夫娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN202111036633.4A priority Critical patent/CN113925830B/zh
Publication of CN109963555A publication Critical patent/CN109963555A/zh
Application granted granted Critical
Publication of CN109963555B publication Critical patent/CN109963555B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种包含美洛昔康的可注射的药物组合物及其制备方法。该药物组合物包含美洛昔康纳米颗粒、表面稳定剂和沉降抑制剂。其稳定性好，不易发生沉降，适于工业化大生产。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201880004385.5A 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法 Active CN109963555B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111036633.4A CN113925830B (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710733082.4 2017-08-24
CN201710733082 2017-08-24
PCT/CN2018/101924 WO2019037757A1 (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111036633.4A Division CN113925830B (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
CN109963555A true CN109963555A (zh) 2019-07-02
CN109963555B CN109963555B (zh) 2021-10-08

Family

ID=65438429

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880004385.5A Active CN109963555B (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法
CN202111036633.4A Active CN113925830B (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111036633.4A Active CN113925830B (zh) 2017-08-24 2018-08-23 一种包含美洛昔康的可注射的药物组合物及其制备方法

Country Status (11)

Country Link
US (1) US20200360268A1 (zh)
EP (1) EP3673897A4 (zh)
JP (1) JP2020531424A (zh)
KR (1) KR20200046018A (zh)
CN (2) CN109963555B (zh)
AU (1) AU2018321744A1 (zh)
BR (1) BR112020001907A2 (zh)
CA (1) CA3070251A1 (zh)
RU (1) RU2020108079A (zh)
TW (1) TW201912148A (zh)
WO (1) WO2019037757A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114504553A (zh) * 2022-02-28 2022-05-17 沈阳信达泰康医药科技有限公司 一种含有卵磷脂的美洛昔康的纳米分散体系
CN114569553A (zh) * 2022-02-28 2022-06-03 沈阳信达泰康医药科技有限公司 一种不含高分子稳定剂的美洛昔康纳米分散体系
CN114796133A (zh) * 2022-05-31 2022-07-29 浙江仙琚萃泽医药科技有限公司 一种注射用药物制剂及其制备方法
CN115300515A (zh) * 2022-08-11 2022-11-08 南京红地生物科技有限公司 一种含有美洛昔康和盐酸曲马多的长效注射液
CN115844820A (zh) * 2022-11-23 2023-03-28 石家庄四药有限公司 一种美洛昔康混悬注射液及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040008B2 (en) 2018-04-04 2021-06-22 Slayback Pharma Llc Pharmaceutical compositions of meloxicam
US20210093642A1 (en) * 2019-09-26 2021-04-01 Cadila Healthcare Limited STABLE AQUEOUS PARENTERAL SOLUTIONS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
CN112823786A (zh) * 2019-11-21 2021-05-21 北京泰德制药股份有限公司 一种含有美洛昔康的药物组合物及应用
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN112587497A (zh) * 2020-12-25 2021-04-02 苏州中化药品工业有限公司 一种美洛昔康混悬液胶囊剂及其制备方法
JP2024517724A (ja) * 2021-04-27 2024-04-23 アニマスキュア インコーポレイテッド． オキシカム系化合物を含む筋疾患の予防または治療用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103690480A (zh) * 2013-12-18 2014-04-02 吉林修正药业新药开发有限公司 治疗类风湿性关节炎、骨性关节炎的美洛昔康注射液及其制备方法
US9345665B2 (en) * 2009-05-27 2016-05-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
US20170157061A1 (en) * 2003-03-03 2017-06-08 Recro Gainesville Llc Nanoparticulate Meloxicam Formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
DE10030345A1 (de) * 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
EP1938803A3 (en) * 2003-03-03 2010-10-27 Elan Pharma International Limited Formulations comprising nanoparticulate meloxican
AU2005313365A1 (en) * 2004-12-06 2006-06-15 Janssen Pharmaceutica N.V. Oral suspension comprising meloxicam
EP1868576A2 (en) 2005-03-17 2007-12-26 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
GB2438287A (en) * 2006-05-19 2007-11-21 Norbrook Lab Ltd Stable aqueous suspension
AP2283A (en) * 2006-05-19 2011-10-31 Norbrook Lab Ltd Stable aqueous suspension.
WO2010121325A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A novel formulation of meloxicam

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157061A1 (en) * 2003-03-03 2017-06-08 Recro Gainesville Llc Nanoparticulate Meloxicam Formulations
US9345665B2 (en) * 2009-05-27 2016-05-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
CN103690480A (zh) * 2013-12-18 2014-04-02 吉林修正药业新药开发有限公司 治疗类风湿性关节炎、骨性关节炎的美洛昔康注射液及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G. HANFT ET AL.,: "Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations", 《INFLAMM. RES., SUPPLEMENT 1》 *
王敏: "美洛昔康干混悬剂的制备及其处方因素考察", 《遵义医学院学报》 *
韦超主编: "《药剂学》", 31 August 2012, 河南科学技术出版社 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114504553A (zh) * 2022-02-28 2022-05-17 沈阳信达泰康医药科技有限公司 一种含有卵磷脂的美洛昔康的纳米分散体系
CN114569553A (zh) * 2022-02-28 2022-06-03 沈阳信达泰康医药科技有限公司 一种不含高分子稳定剂的美洛昔康纳米分散体系
CN114796133A (zh) * 2022-05-31 2022-07-29 浙江仙琚萃泽医药科技有限公司 一种注射用药物制剂及其制备方法
CN114796133B (zh) * 2022-05-31 2023-08-25 浙江萃泽医药科技有限公司 一种注射用药物制剂及其制备方法
CN115300515A (zh) * 2022-08-11 2022-11-08 南京红地生物科技有限公司 一种含有美洛昔康和盐酸曲马多的长效注射液
CN115844820A (zh) * 2022-11-23 2023-03-28 石家庄四药有限公司 一种美洛昔康混悬注射液及其制备方法
CN115844820B (zh) * 2022-11-23 2023-08-29 石家庄四药有限公司 一种美洛昔康混悬注射液及其制备方法

Also Published As

Publication number Publication date
AU2018321744A1 (en) 2020-04-02
CN113925830A (zh) 2022-01-14
CN113925830B (zh) 2023-07-14
EP3673897A4 (en) 2021-05-05
US20200360268A1 (en) 2020-11-19
CN109963555B (zh) 2021-10-08
KR20200046018A (ko) 2020-05-06
CA3070251A1 (en) 2019-02-28
EP3673897A1 (en) 2020-07-01
RU2020108079A3 (zh) 2021-11-22
RU2020108079A (ru) 2021-09-24
BR112020001907A2 (pt) 2020-08-04
WO2019037757A1 (zh) 2019-02-28
TW201912148A (zh) 2019-04-01
JP2020531424A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
CN109963555A (zh) 一种包含美洛昔康的可注射的药物组合物及其制备方法
Jacob et al. Emerging role of nanosuspensions in drug delivery systems
kumar Nagabandi et al. Liquisolid compacts: a novel approach to enhance bioavailability of poorly soluble drugs
CN101636150B (zh) 难水溶性医疗用有机化合物微粒子的制造方法
US9504652B2 (en) Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
CA2492488A1 (en) Liquid dosage compositions of stable nanoparticulate active agents
CN101212954A (zh) 纳米粒氯吡格雷制剂
CA2622758A1 (en) Nanoparticulate aripiprazole formulations
CN101484170A (zh) 包含纳米颗粒萘普生和控释氢可酮的组合物
WO2020034989A1 (zh) 一种可注射的药物组合物及其制备方法
Han et al. A new approach to produce drug nanosuspensions CO2-assisted effervescence to produce drug nanosuspensions
JP6666352B2 (ja) デュタステリド含有固体分散体及びこれを含む組成物
WO2007146943A2 (en) Nanoparticulate kinase inhibitor formulations
CN114432242B (zh) 一种阿普斯特纳米晶组合物及制备方法
US20210251902A1 (en) Delamanid-containing composition
CN102772365B (zh) 4-(4-(3-三氟甲基)苯甲酰胺基苯氧基)-2-(甲基氨甲酰基)吡啶纳米混悬剂及其制法和应用
Abd Elkarim et al. Novel nanosized Diacerein proliposomes for oral delivery: Development and in vitro/in vivo evaluation
MX2007016151A (es) Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos.
Sanas et al. Exploring the Potential of Ketoprofen Nanosuspension: In Vitro and In Vivo Insights into Drug Release and Bioavailability
Shama et al. Asian Journal of Pharmaceutical Education and Research
CN106138052A (zh) 一种沙利度胺制剂及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009384

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant